U.S. markets close in 23 minutes
  • S&P 500

    3,631.88
    -3.53 (-0.10%)
     
  • Dow 30

    29,877.96
    -168.28 (-0.56%)
     
  • Nasdaq

    12,107.13
    +70.34 (+0.58%)
     
  • Russell 2000

    1,848.40
    -5.13 (-0.28%)
     
  • Crude Oil

    45.61
    +0.70 (+1.56%)
     
  • Gold

    1,806.50
    +1.90 (+0.11%)
     
  • Silver

    23.40
    +0.10 (+0.43%)
     
  • EUR/USD

    1.1925
    +0.0028 (+0.24%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • GBP/USD

    1.3385
    +0.0026 (+0.20%)
     
  • USD/JPY

    104.4350
    -0.0450 (-0.04%)
     
  • BTC-USD

    18,881.74
    -159.10 (-0.84%)
     
  • CMC Crypto 200

    373.15
    +2.64 (+0.71%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

DotLab Announces Scientific Advisory Board

·3 min read

Advisors Bring Deep Experience Across the Women's Health Industry in Biomarker Discovery and Development and the Treatment of Pelvic Pain and Infertility

SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Today, DotLab -- a healthcare technology company on the front lines of research and development in women's health -- announced the formation of its Scientific Advisory Board (SAB) to provide guidance on the development of DotLab's non-invasive test to aid in the diagnosis of endometriosis.

DotLab seeks to fundamentally shift and improve today’s standards by bringing personalized medicine to women’s healthcare, starting with its non-invasive, accurate test for endometriosis. (PRNewsfoto/DotLab)
DotLab seeks to fundamentally shift and improve today’s standards by bringing personalized medicine to women’s healthcare, starting with its non-invasive, accurate test for endometriosis. (PRNewsfoto/DotLab)

The SAB is composed of Key Opinion Leaders in women's health, including clinical research experts, thought-leaders in obstetrics & gynecology and reproductive endocrinology, and industry experts.

Formalizing the SAB builds on the progress DotLab has made this year, which includes the publication of data in the American Journal of Obstetrics & Gynecology, demonstrating high accuracy of its microRNA approach for evaluating the presence of endometriosis.

"We believe the collective experience of these highly-distinguished experts in women's health will be an enormous asset to DotLab's efforts to overcome the barriers to diagnosis in endometriosis, which can result in delays in receiving treatment of up to 10 years," said Heather Bowerman, CEO of DotLab.

The members of the SAB are as follows:

  • Kristof Chwalisz, MD PhD, internationally renowned pre-clinical and clinical researcher in the field of women's health with a focus on new therapies for endometriosis, uterine fibroids and uterine bleeding disorders

  • Anula Jayasuriya, MD PhD MBA, successful private equity executive and venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience

  • Thomas Musci, MD, former Chief Medical Officer at Ariosa Diagnostics (acquired by Roche), and former faculty member at the University of California, San Francisco (UCSF)

  • Harold Sauer, MD, Chairman of the Department of Obstetrics and Gynecology at Bridgeport Hospital, part of the Yale New Haven Health System

  • Eric Surrey, MD, Board Certified Reproductive Endocrinologist and Medical Director at Colorado Center for Reproductive Medicine (CCRM) and past President of the Society for Assisted Reproductive Technology (SART)

  • Robert Taylor, MD PhD, Professor of Obstetrics and Gynecology and Assistant Dean and Director of the MD-PhD Program at the University at Buffalo

For more information about the members of the scientific advisory board, visit www.dotlab.com/about.

About Endometriosis

Endometriosis is a chronic, progressive disease affecting approximately one in ten women of reproductive age. The diagnosis of endometriosis is associated with numerous challenges which include a lack of symptoms that are disease-specific; the "normalization" of symptoms such as painful periods; and the need for a surgical procedure (laparoscopy) performed under general anesthesia to establish a definitive diagnosis. These challenges lead to a delay from time of first symptom onset to diagnosis ranging from 4 to 11 years. During this time, treatment to alleviate symptoms is delayed and disease progression can occur. Estimates of direct and indirect costs of endometriosis in the US range from $22 billion to $69 billion. The availability of non-invasive tools to aid in the diagnosis of endometriosis could reduce the time to diagnosis, years of discomfort, disease progression, and associated comorbidities and healthcare costs.

About DotLab

DotLab is a female-founded, women's healthcare technology company whose mission is to advance women's health into an era of precision medicine by developing breakthrough, actionable technologies that lead to better outcomes. DotLab's first product, DotEndo, offers a non-invasive solution to aid in the diagnosis of active endometriosis. DotEndo overcomes the complex challenges posed by heterogeneity in endometriosis by using a multi-analyte, algorithmic approach. DotLab is headquartered in San Francisco, CA and has a clinical laboratory in Branford, CT.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/dotlab-announces-scientific-advisory-board-301161076.html

SOURCE DotLab